Isomorphic Labs, an Alphabet spinoff developing an AI platform for drug discovery, is reportedly in talks to raise new funding. The reported target valuation is $40 billion to $50 billion. If the round closes, Isomorphic’s partnerships and development of IsoDDE would likely accelerate as investors fund the company’s work.
Trevor Martin of Mammoth Biosciences describes how the company uses AI to search large protein spaces and engineer smaller CRISPR systems for genetic disease work. The discussion highlights the key proof hurdle: validating what actually survives contact with a human body. The result is a clearer focus on biological validation rather than AI alone solving everything.
STFC’s Daresbury Laboratory welcomed 7 health-tech startups into its DeepTech Catalyst Health (DTC Health) programme to develop patient diagnosis, treatment, and support tools. The startups receive a tailored support package worth up to £70,000, as the programme was launched in 2024 with £1.8 million funding. The programme expands access to AI and prototyping facilities and aims to move these early-stage products toward real-world healthcare delivery and jobs.
The Wall Street Journal·1 week ago·
36
● 3 sources
Biohub partnered with the US Department of Energy and the National Institutes of Health to invest in biological data intended for AI models. The effort involves $1.8 billion in funding. It will expand lab measurement, modeling, and computation alongside coordinated datasets and repositories to make the data usable for disease research.
Finches, a female-founded startup, raised €2 million in pre-seed funding to launch AI-driven software that issues crop-risk alerts for food manufacturers ahead of shortages. The round was co-led by High-Tech Gründerfonds and Vanagon, with Bayern Kapital joining as a new investor. The company will use the money to accelerate product development and expand sales operations.
Every AI story that matters,
in your inbox by 8am.
TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the
day in two minutes. Follow companies and topics for alerts, or get the
briefing in Slack. Free, no spam, unsubscribe anytime.
Reading TLDRocket needs no cookies, and the readership counts we rely on come from
our own cookieless analytics. Google Analytics is the exception: it sets cookies and
reports to Google, so it stays switched off until you allow it. You can change your
mind any time from “Cookie settings” in the footer.
Strictly necessary
Session security and form protection (tldrocket-session,
XSRF-TOKEN, 2 hours). The site cannot work without them,
so they need no consent.
Always on
Google Analytics 4 (_ga,
_ga_<id>, up to 2 years). Measures which
stories and sections readers use. Google acts as a third-party processor and may
store the data outside the EU. No advertising, no profiling, no data sold.